You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.



Primary Hyperoxaluria: Assessing Practice Patterns in Diagnosis and Management

  • Authors: John Lieske, MD
  • CME / ABIM MOC Released: 12/5/2022
  • Valid for credit through: 12/5/2023, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for nephrologists, pediatricians, emergency medicine physicians, and primary care physicians (PCPs).

The goal of this activity is for learners to be better able to self-assess their learning needs regarding diagnosis, treatment and management of primary hyperoxaluria type 1 (PH1).

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Diagnostic approach to PH1
  • Self-assess learning needs related to
    • Managing PH1


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


  • John Lieske, MD

    Professor of Medicine
    Mayo Clinic
    Rochester, Minnesota



    John Lieske, MD, has the following relevant financial relationships:
    Consultant or advisor for: Alnylam; BioMarin; Cantera/Bridgebio; Chinook; Dicerna/Novo Nordisk; Federation Bio; Intellia; Novobiome; Oxidien; Precision Biosciences; Synlogic
    Contracted researcher for: Allena; Arkray; Dicerna/Novo Nordisk; lnylam; Novobiome; OxThera; Siemens; Synlogic


  • Jennifer Hakkarainen, PA-C

    Medical Education Director, Medscape, LLC


    Jennifer Hakkarainen, PA-C, has no relevant financial relationships.

  • Jenny Engelmoer

    Medical Writer, Medscape, LLC


    Jenny Engelmoer has no relevant financial relationships.

Compliance Reviewer

  • Susan L. Smith, MN, PhD

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Susan L. Smith, MN, PhD, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements


Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Primary Hyperoxaluria: Assessing Practice Patterns in Diagnosis and Management

Authors: John Lieske, MDFaculty and Disclosures

CME / ABIM MOC Released: 12/5/2022

Valid for credit through: 12/5/2023, 11:59 PM EST



  1. Milliner D, et al. Primary hyperoxaluria type 1. In: Adam MP, et al. GeneReviews. University of Washington; 2022. Updated February 10, 2022. Accessed November 8, 2022.
  2. Cochat P, at al; Société de Néphrologie and the Société de Néphrologie Pédiatrique. Epidemiology of primary hyperoxaluria type 1. Nephrol Dial Transplant. 1995;10(Suppl 8):3-7.
  3. Soliman NA, et al. Clinical spectrum of primary hyperoxaluria type 1: Experience of a tertiary center. Nephrol Ther. 2017;13:176-182.
  4. van Woerden CS, et al. Primary hyperoxaluria type 1 in The Netherlands: Prevalence and outcome. Nephrol Dial Transplant. 2003;18:273-279.
  5. Cochat P, et al. Primary hyperoxaluria type 1: indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant. 2012;27:1729-1736.
  6. Daudon M, et al. Peculiar morphology of stones in primary hyperoxaluria. N Engl J Med. 2008;359:100-102.
  7. Sikora P, et al. [13C2]oxalate absorption in children with idiopathic calcium oxalate urolithiasis or primary hyperoxaluria. Kidney Int. 2008;73:1181-1186.
  8. Edvardsson VO, et al. Hereditary causes of kidney stones and chronic kidney disease. Pediatr Nephrol. 2013;28:1923-1942.
  9. Sas DJ, et al. New insights regarding organ transplantation in primary hyperoxaluria type 1. Kidney Int Rep. 2022;7:146-148.
  10. Noonan SC, et al. Oxalate content of foods and its effect on humans. Asia Pac J Clin Nutr. 1999;8:64-74.
  11. Holmes RP, et al. Estimation of the oxalate content of foods and daily oxalate intake. Kidney Int. 2000;57:1662-1667.
  12. Tang X, et al. Oxalate quantification in hemodialysate to assess dialysis adequacy for primary hyperoxaluria. Am J Nephrol. 2014;39:376-382.
  13. Sas DJ, et al. Natural history of clinical, laboratory, and echocardiographic parameters of a primary hyperoxaluria cohort on long term hemodialysis. Front Med (Lausanne). 2021;8:592357.
  14. Cellini B, et al. Molecular insights into primary hyperoxaluria type 1 pathogenesis. Front Biosci (Landmark Ed). 2012;17:621-634.
  15. Lumasiran [prescribing information] Approved 2020. Revised October 2022.
  16. Bacchetta J, et al. Primary hyperoxaluria type 1: novel therapies at a glance. Clin Kidney J. 2022;15(Suppl 1):i17-i22.
  17. Dejban P, et al. New therapeutics for primary hyperoxaluria type 1. Curr Opin Nephrol Hypertens. 2022;31:344-350.
  18. Garrelfs SF, et al. Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N Engl J Med. 2021;384:1216-1226.
  19. Baum MA, et al. PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2. Kidney Int. 2022. doi:10.1016/j.kint.2022.07.025 [Epub ahead of print]
« Return to: Primary Hyperoxaluria: Assessing Practice Patterns in Diagnosis and Management
  • Print